Zenith
Epigenetics

Zenith Epigenetics Corp. is a research and development biotechnology company focused on new and innovative drugs by leveraging its proprietary epigenetics platform. The company's epigenetic drug discovery platform functions by inhibiting BET bromodomains, having the potential to impact multiple diseases including autoimmune and oncology.

Learn More

News Highlights

Zenith Epigenetics Appoints Julie Cherrington as President and CEO

July 23, 2014 - Zenith Epigenetics Corp. ("Zenith" or the "Company") today announced that it has appointed Julie Cherrington PhD to act as the President and Chief Executive Officer of Zenith Epigenetics Corp. Julie has an extensive background leading companies focused on the discovery and development of novel cancer therapeutics and is well-versed in the challenges of developing drugs and advancing them into the clinic and through to commercialization.  Her accomplished employment record includes past notable positions such as CEO of Pathway Therapeutics Inc., President of Phenomix Corporation, Vice President, Preclinical Research and Exploratory Development SUGEN/Pharmacia/Pfizer, and Director, Virology at Gilead Sciences. Notably, Julie was a key contributor to the successful development of multiple FDA approved products including anti-virals (Vistide™, Viread™, Hepsera™) and anti-cancer agents (SUTENT™, Palladia™).

Read More

Zenith Epigenetics Closes $4.6 million Private Placement

July 23, 2014 - Zenith Epigenetics Corp. ("Zenith" or the "Company") today announced that it has closed a private placement of 4.3 million common shares at a price of US$1.00 per share for gross proceeds of CAD$4.6 million (the "Private Placement"). NGN BioMed Opportunity II, L.P. ("NGN") subscribed for 1,000,000 common shares. The shares are subject to a four month hold period.

After giving effect to the Private Placement, NGN holds 11,103,004 common shares of Zenith, representing approximately 12.2% of Zenith's issued and outstanding common shares. NGN also holds 350,000 common share purchase warrants of Zenith.

Read More
Events
Jul
22

EpiCongress Boston 2014 (July 22 - 24)

We are proud to announce that we are the Lead Sponsor for this conference. 

Read More Add This to my Calendar

Sign Up For Updates

Please submit your name and email for latest news. To unsubscribe from alerts, please click here.

Name*
Email Address*